%0 Journal Article
%A DeTemple, Viola K
%A Kaatz, Martin
%A Stockfleth, Eggert
%A Scheel, Christina
%A Angela, Yenny
%A Gutzmer, Ralf
%A Leiter, Ulrike
%A Meier, Friedegund
%A Schadendorf, Dirk
%A Livingstone, Elisabeth
%A Gebhardt, Christoffer
%A von Wasielewski, Imke
%A Weichenthal, Michael
%A Mohr, Peter
%A Hassel, Jessica
%A Pföhler, Claudia
%A Simon, Jan Christoph
%A Jochims, Franziska
%A Terheyden, Patrick
%A Ulrich, Jens
%A Haferkamp, Sebastian
%A Drexler, Konstantin
%A Schilling, Bastian
%A Glutsch, Valerie
%A Heinzerling, Lucie
%A Berking, Carola
%A Ugurel, Selma
%A Tomsitz, Dirk
%T Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.
%J European journal of cancer
%V 225
%@ 0959-8049
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2025-01334
%P 115590
%D 2025
%X The anti-PD1 antibody (PD1i) cemiplimab is approved as second-line treatment for locally advanced or metastatic basal cell carcinoma (BCC), resulting in an ORR of 20-30 
%K Basal cell carcinoma (Other)
%K Cemiplimab (Other)
%K Hedgehog inhibitor (Other)
%K Immune checkpoint inhibitor (Other)
%K Real world data (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40580809
%R 10.1016/j.ejca.2025.115590
%U https://inrepo02.dkfz.de/record/302794